CAMBRIDGE, Mass. , April 5, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $140 million on the company's common stock. This special dividend will be paid from the proceeds of the
Completes Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen<br>Merrimack Plans to Return $140 Million to Stockholders through Special Cash Dividend<br>To Set Record Date for Payment of Special Cash Dividend in Due Course
CAMBRIDGE, Mass. , March 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack") announced that, at its Special Meeting of Stockholders held today, its stockholders voted to approve the asset sale with Ipsen S.A. under which Merrimack will: Sell to Ipsen its first
Presentations to include data on MM-310, a novel antibody-directed nanotherapeutic targeting EphA2, and istiratumab (MM-141), a monoclonal bispecific antibody that acts as a tetravalent inhibitor of IGF1-R and HER3
CAMBRIDGE, Mass. , March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals , Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the
CAMBRIDGE, Mass. , March 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its fourth quarter and full year 2016 financial results for the period ended December 31, 2016 . Key Recent Events As announced on January 8, 2017 , Merrimack entered into an asset
CAMBRIDGE, Mass. , Feb. 22, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Fourth Quarter 2016 investor conference call and webcast at 8:30 a.m., Eastern time, on Wednesday, March 1. The call will cover an update on Merrimack's
Company to Sell ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion<br>$200 Million to Be Returned to Stockholders through Special Cash Dividend; Board Commits to Returning Amounts Received from $450 Million in Future Milestones<br>Refocused Research & Development Company Will Have Resources to Advance Lead Pipeline Candidates MM-121, MM-141 and MM-310
CAMBRIDGE, Mass. , Jan. 4, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2017 , at 3:00 PM Pacific Time .